Epigenomics AG

EANS-News: Epigenomics Septin9 Biomarker detects Colon Cancer equally in both sides of the Colon

--------------------------------------------------------------------------------
  Corporate news transmitted by euro adhoc. The issuer/originator is solely
  responsible for the content of this announcement.
--------------------------------------------------------------------------------
New Products/Company Information/molecular diagnostics


Berlin, Germany, and Seattle, WA, U.S.A., February 16, 2012 (euro adhoc) -
Epigenomics AG (Frankfurt Prime Standard: ECX), the German-American cancer
molecular diagnostics company, is pleased to announce the results from a study
conducted in collaboration with Professor Dr. Béla Molnár and his team from the
2nd Department of Internal Medicine of Semmelweis University in Budapest,
Hungary. In the study, the blood based detection of methylated Septin9 in
colorectal cancer (CRC) cases was assessed in the left and right side of the
colon.

In a blinded case control study of a total of 184 study participants, plasma
from 92 CRC cases (56 left-, 36 right-sided cases) was analyzed and methylated
Septin9 was detected in a total of 88 cancer cases, representing 96% sensitivity
for overall CRC detection at a specificity of 85%. The control arm consisted of
92 samples of individuals with no evidence of disease as verified by
colonoscopy. Sensitivity for detection of left- and right-sided cases was 96%
and 94% respectively, thus showing no significant difference between cancer
detection in either side of the colon. 

In a subset of 39 subjects that received a fecal occult blood test (FOBT,
Hemoccult II stool test) in addition to a Septin9 test, the sensitivities for
FOBT for the detection of 12 left- sided cases was 83% and 50% for the 10
right-sided cases in this study. Overall, sensitivity for FOBT was 68% and
specificity was 71%.

The complete data will be submitted by Prof. Molnár for publication in a peer
reviewed journal in due course.

Dr. Jürgen Beck, Senior Vice President of Medical Affairs commented: "These
results are in line with previously reported performance evaluations for CRC
detection in case control studies performed by Epigenomics and other parties.
They reflect the value and the superiority of blood based testing of methylated
Septin9 for early detection of colorectal cancer, independently of the
localization of the cancerous lesion"

- Ends -

Further Information

Contact Epigenomics AG

Antje Zeise
Manager IR | PR  
Epigenomics AG 
Tel +49 (0) 30 24345 368 
ir@epigenomics.com  
www.epigenomics.com

About Epigenomics

Epigenomics (www.epigenomics.com) is a molecular diagnostics company developing
and commercializing a pipeline of proprietary products for cancer. The Company's
products enable doctors to diagnose cancer earlier and more accurately, leading
to improved outcomes for patients. Epigenomics' lead product, Epi proColon®, is
a blood-based test for the early detection of colorectal cancer, which is
currently marketed in Europe and is in development for the U.S.A. The Company's
technology and products have been validated through multiple partnerships with
leading global diagnostic companies including Abbott, QIAGEN, Sysmex, and Quest
Diagnostics. Epigenomics is an international company with operations in Europe
and the U.S.A.

Epigenomics legal disclaimer

This communication expressly or implicitly contains certain forward-looking
statements concerning Epigenomics AG and its business. Such statements involve
certain known and unknown risks, uncertainties and other factors which could
cause the actual results, financial condition, performance or achievements of
Epigenomics AG to be materially different from any future results, performance
or achievements expressed or implied by such forward-looking statements.
Epigenomics AG is providing this communication as of this date and does not
undertake to update any forward-looking statements contained herein as a result
of new information, future events or otherwise. 

The information contained in this communication does not constitute nor imply an
offer to sell or transfer any product, and no product based on this technology
is currently available for sale by Epigenomics in the United States or Canada.
The analytical and clinical performance characteristics of any Epigenomics
product based on this technology which may be sold at some future time in the
U.S. have not been established.


Further inquiry note:
Antje Zeise | CIRO 
Manager IR/PR 
Epigenomics AG
Tel: +49 30 24345 386
antje.zeise@epigenomics.com

end of announcement                               euro adhoc 
--------------------------------------------------------------------------------


company:     Epigenomics AG
             Kleine Präsidentenstraße 1
             D-10178 Berlin
phone:       +49 30 24345-0
FAX:         +49 30 24345-555
mail:     ir@epigenomics.com
WWW:      http://www.epigenomics.com
sector:      Biotechnology
ISIN:        DE000A1K0516
indexes:     Prime All Share, Technology All Share
stockmarkets: free trade: Berlin, München, Hamburg, Düsseldorf, Stuttgart,
             regulated dealing/prime standard: Frankfurt 
language:   English
 



Weitere Meldungen: Epigenomics AG

Das könnte Sie auch interessieren: